{"id":70719,"date":"2026-05-12T09:49:37","date_gmt":"2026-05-12T09:49:37","guid":{"rendered":"https:\/\/medsbase.com\/?post_type=product&#038;p=70719"},"modified":"2026-05-21T07:14:10","modified_gmt":"2026-05-21T07:14:10","slug":"follistatin-344","status":"publish","type":"product","link":"https:\/\/medsbase.com\/cs\/product\/follistatin-344\/","title":{"rendered":"Follistatin 344"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background: #fff8e1; border-left: 4px solid #f5a623; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<h3 style=\"margin: 0 0 8px 0; font-size: 16px; color: #1a4a6b;\">Rychl\u00e1 odpov\u011b\u010f \u2014 Co je Follistatin 344?<\/h3>\n<p style=\"margin: 0;\"><strong>Follistatin 344<\/strong> (FST-344) je 344-aminokyselinov\u00fd rekombinantn\u00ed glykoprotein a del\u0161\u00ed ze dvou hlavn\u00edch sest\u0159ihov\u00fdch izoforem lidsk\u00e9ho follistatinu. Je to kanonick\u00fd endogenn\u00ed antagonista myostatinu (GDF-8) a aktivinu, pou\u017e\u00edvan\u00fd v publikovan\u00fdch v\u00fdzkumech zab\u00fdvaj\u00edc\u00edch se svalovou hypertrofi\u00ed, sarkopeni\u00ed, preklinick\u00fdmi modely svalov\u00e9 dystrofie a signaliza\u010dn\u00ed osou aktivin\/myostatin. Dod\u00e1v\u00e1 se v lyofilizovan\u00fdch vialk\u00e1ch po 1 mg v\u00fdhradn\u011b pro laboratorn\u00ed v\u00fdzkum.<\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background: #f4f8fb; border: 1px solid #d8e3eb; padding: 12px 16px; margin: 16px 0; border-radius: 4px; font-size: 14px;\"><strong>Co z\u00edsk\u00e1te s MedsBase:<\/strong> V\u00fdzkumn\u00fd lyofilizovan\u00fd rekombinantn\u00ed protein \u00b7 HPLC \u010distota \u226595 % (COA na vy\u017e\u00e1d\u00e1n\u00ed) \u00b7 Diskr\u00e9tn\u00ed teplotn\u011b stabiln\u00ed balen\u00ed \u00b7 Celosv\u011btov\u00e1 p\u0159eprava peptid\u016f \u00b7 1 400+ ov\u011b\u0159en\u00fdch <a href=\"https:\/\/medsbase.com\/cs\/reviews\/\">recenz\u00ed z\u00e1kazn\u00edk\u016f<\/a><\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size: 14px; color: #444; margin: 8px 0 18px;\">\ud83d\udce6 Ka\u017ed\u00e1 objedn\u00e1vka je pokryta na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\"><strong>Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/strong><\/a> \u2014 pokud va\u0161e z\u00e1silka nedoraz\u00ed do 20 pracovn\u00edch dn\u016f, p\u0159epos\u00edl\u00e1me ji.<\/p>\n<table class=\"medsbase-spec-table\" style=\"width: 100%; border-collapse: collapse; margin: 18px 0; font-size: 14px;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 8px 12px; text-align: left; width: 30%;\">Specifikace<\/th>\n<th style=\"padding: 8px 12px; text-align: left;\">Detail<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>CAS \u010d\u00edslo<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">80449-31-6 (follistatin)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Typ<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Rekombinantn\u00ed glykoprotein (344-aminokyselinov\u00e1 FST-344 splicovan\u00e1 izoforma lidsk\u00e9ho follistatinu)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item7<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">~37 kDa (zral\u00e1 glykosylovan\u00e1 forma; ~38\u201342 kDa pozorovan\u00e9 rozmez\u00ed na SDS-PAGE v z\u00e1vislosti na glykyla\u010dn\u00edm stavu)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Struktura<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">N-termin\u00e1ln\u00ed heparin-vazebn\u00e1 dom\u00e9na n\u00e1sledovan\u00e1 t\u0159emi follistatinov\u00fdmi dom\u00e9nami (FSD1, FSD2, FSD3), z nich\u017e ka\u017ed\u00e1 obsahuje EGF-podobnou a Kazal-podobnou subdom\u00e9nu; bohat\u00e1 na cystein, v\u00edce intramolekul\u00e1rn\u00edch disulfidov\u00fdch vazeb<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item11<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyofilizovan\u00fd rekombinantn\u00ed protein (b\u00edl\u00fd a\u017e sv\u011btle \u017elut\u00fd)<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>item13<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">\u226595 % (ov\u011b\u0159eno HPLC, COA na vy\u017e\u00e1d\u00e1n\u00ed)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Skladov\u00e1n\u00ed<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Lyofilizovan\u00fd: 2\u20138 \u00b0C (lednice) pro pracovn\u00ed z\u00e1sobu; \u221220 \u00b0C pro dlouhodob\u00e9 skladov\u00e1n\u00ed neotev\u0159en\u00fdch vialek. Rekonstituovan\u00fd: 2\u20138 \u00b0C, pou\u017e\u00edt do ~30 dn\u016f. Chr\u00e1nit p\u0159ed sv\u011btlem. Nen\u00ed vhodn\u00e9 zmrazovat a rozmrazovat rekonstituovan\u00fd roztok \u2014 rekombinantn\u00ed proteiny jsou obzvl\u00e1\u0161t\u011b citliv\u00e9 na denaturaci zp\u016fsobenou zmrazen\u00edm a rozmrazen\u00edm.<\/td>\n<\/tr>\n<tr style=\"background: #fff;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Rozpustnost<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Bakteriostatick\u00e1 voda (doporu\u010deno) nebo steriln\u00ed voda pro krat\u0161\u00ed dobu pou\u017eit\u00ed. Nosn\u00fd protein (BSA, 0,1 %) voliteln\u00fd pro pracovn\u00ed \u0159ed\u011bn\u00ed, aby se minimalizovaly ztr\u00e1ty adsorpc\u00ed.<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0; width: 30%;\"><strong>Pouze pro v\u00fdzkum<\/strong><\/td>\n<td style=\"padding: 8px 12px; border-bottom: 1px solid #e0e0e0;\">Pouze pro laboratorn\u00ed v\u00fdzkum. Nen\u00ed ur\u010deno pro diagnostick\u00e9 nebo terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed nebo zv\u00ed\u0159at.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><!-- \/medsbase-tldr-answer --><\/p>\n<h2>Co je Follistatin 344?<\/h2>\n<p><strong>Follistatin 344<\/strong> (\u010dasto zkr\u00e1cen\u011b FST-344) je rekombinantn\u00ed 344-aminokyselinov\u00fd glykoprotein a del\u0161\u00ed ze dvou hlavn\u00edch fyziologick\u00fdch splicovan\u00fdch izoforem lidsk\u00e9ho follistatinu \u2014 druhou je FST-288, krat\u0161\u00ed 288-aminokyselinov\u00e1 membr\u00e1nov\u011b v\u00e1zan\u00e1 forma. Endogenn\u00ed follistatin byl poprv\u00e9 izolov\u00e1n v roce 1987 z folikul\u00e1rn\u00ed tekutiny vaje\u010dn\u00edk\u016f prasat Esch et al. (PNAS) a Robertson et al. (Biochem Biophys Res Commun) jako faktor, kter\u00fd selektivn\u011b inhibuje sekreci folikuly stimuluj\u00edc\u00edho hormonu (FSH), co\u017e dalo proteinu jeho n\u00e1zev. Mechanistick\u00e1 role \u2014 vysok\u00e1 afinita vazby a neutralizace aktivinu a myostatinu \u2014 byla charakterizov\u00e1na v n\u00e1sleduj\u00edc\u00edm desetilet\u00ed.<\/p>\n<p>FST-344 je cirkuluj\u00edc\u00ed, sekretovan\u00e1 izoforma s heparin-vazebnou N-termin\u00e1ln\u00ed dom\u00e9nou n\u00e1sledovanou t\u0159emi cystein-bohat\u00fdmi follistatinov\u00fdmi dom\u00e9nami (FSD1, FSD2, FSD3), kter\u00e9 spole\u010dn\u011b tvo\u0159\u00ed vazebn\u00fd povrch pro aktivin a myostatin. Rekombinantn\u00ed \u0159et\u011bzec o 344 zbytc\u00edch m\u00e1 zralou hmotnost p\u0159ibli\u017en\u011b 37 kDa, s apparentn\u00ed molekulovou hmotnost\u00ed na SDS-PAGE v rozmez\u00ed 38 a\u017e 42 kDa v z\u00e1vislosti na glykyla\u010dn\u00edm stavu rekombinantn\u00edho expresn\u00edho syst\u00e9mu. CAS \u010d\u00edslo 80449-31-6. Protein je dod\u00e1v\u00e1n jako vysoce \u010dist\u00fd lyofilizovan\u00fd pr\u00e1\u0161ek pro rekonstituci s bakteriostatickou vodou. Follistatin nen\u00ed <strong>FDA, EMA, MHRA ani \u017e\u00e1dn\u00fdm jin\u00fdm v\u00fdznamn\u00fdm regul\u00e1torem pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed. V\u00fdzkumn\u00fd DSIP prod\u00e1van\u00fd zde je dod\u00e1v\u00e1n<\/strong> schv\u00e1len FDA, EMA, MHRA ani \u017e\u00e1dn\u00fdm jin\u00fdm v\u00fdznamn\u00fdm regul\u00e1torem pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed. V\u00fdzkumn\u00fd follistatin 344 prod\u00e1van\u00fd zde je dod\u00e1v\u00e1n <strong>ur\u010den pouze pro laboratorn\u00ed v\u00fdzkum<\/strong> a nen\u00ed ur\u010den pro pod\u00e1v\u00e1n\u00ed lidem nebo zv\u00ed\u0159at\u016fm. Pro souvisej\u00edc\u00ed v\u00fdzkum anabolick\u00fdch a r\u016fstov\u00fdch os, viz na\u0161e <a href=\"https:\/\/medsbase.com\/cs\/igf-1-lr3\/\">IGF-1 LR3<\/a> produktovou str\u00e1nku.<\/p>\n<h2>Mechanismus \u00fa\u010dinku \u2014 Antagonismus myostatinov\u00e9 a aktivinov\u00e9 dr\u00e1hy<\/h2>\n<p>Co \u010din\u00ed follistatin 344 mechanisticky unik\u00e1tn\u00edm mezi proteiny pro v\u00fdzkum sval\u016f, je jeho <strong>multi-c\u00edlov\u00fd vazebn\u00fd profil<\/strong> nap\u0159\u00ed\u010d superrodinou TGF-\u03b2 \u2014 ka\u017ed\u00e1 vazebn\u00e1 interakce s ligandem p\u0159isp\u00edv\u00e1 k pozorovan\u00e9mu hypertrofick\u00e9mu a r\u016fstov\u011b modula\u010dn\u00edmu fenotypu v publikovan\u00fdch studi\u00edch:<\/p>\n<ul>\n<li><strong>Sekvestrace myostatinu (GDF-8) \u2014 osa svalov\u00e9 hypertrofie<\/strong> \u2014 Follistatin v\u00e1\u017ee myostatin (tak\u00e9 naz\u00fdvan\u00fd GDF-8) s vysokou afinitou, stericky blokuje jeho interakci s aktivinov\u00fdm receptorem typu II (ActRIIB). Myostatin je kanonick\u00fd endogenn\u00ed negativn\u00ed regul\u00e1tor r\u016fstu sval\u016f: knockoutovan\u00e9 my\u0161i vykazuj\u00ed dramatickou svalovou hypertrofii (fenotyp \u201cdvojit\u00e9ho svalstva\u201d) a p\u0159irozen\u011b myostatin-deficientn\u00ed plemena skotu (Belgick\u00e1 modr\u00e1, Piemontese) vykazuj\u00ed stejn\u00fd efekt. Neutralizac\u00ed myostatinu follistatin odstra\u0148uje brzdu synt\u00e9zy svalov\u00fdch protein\u016f, co\u017e vede k hypertrofii ve v\u00fdzkumn\u00fdch modelech. Toto je nej\u010dast\u011bji citovan\u00fd mechanismus v literatu\u0159e o v\u00fdzkumu sval\u016f.<\/li>\n<li><strong>Sekvestrace aktivinu A a B \u2014 reproduk\u010dn\u00ed, ovari\u00e1ln\u00ed a hypofyz\u00e1rn\u00ed signalizace<\/strong> \u2014 P\u016fvodn\u00ed charakterizovanou funkc\u00ed follistatinu byla vazba a neutralizace aktivinu, p\u0159\u00edbuzn\u00e9ho \u010dlena superrodiny TGF-\u03b2, kter\u00fd stimuluje sekreci FSH z hypof\u00fdzy, \u0159\u00edd\u00ed v\u00fdvoj ovari\u00e1ln\u00edch folikul\u016f a p\u016fsob\u00ed jako regul\u00e1tor mnoha typ\u016f bun\u011bk. Vazbou na aktivin A, B a AB heterodimery follistatin posouv\u00e1 rovnov\u00e1hu aktivin\/inhibin ve v\u00fdzkumn\u00fdch modelech a moduluje downstream signalizaci Smad2\/Smad3.<\/li>\n<li><strong>Modulace GDF-11 a \u0161ir\u0161\u00ed superrodiny TGF-\u03b2<\/strong> \u2014 Follistatin tak\u00e9 v\u00e1\u017ee GDF-11 (bl\u00edzce p\u0159\u00edbuzn\u00fd myostatinu) s pon\u011bkud ni\u017e\u0161\u00ed afinitou, spolu s dal\u0161\u00edmi \u010dleny superrodiny TGF-\u03b2. GDF-11 je st\u00e1le v\u00edce studov\u00e1n ve v\u00fdzkumu st\u00e1rnut\u00ed, proto\u017ee jeho endogenn\u00ed hladiny s v\u011bkem klesaj\u00ed a jeho modulace je spojena s v\u011bkem souvisej\u00edc\u00edmi fenotypy srdce a CNS. Follistatin 344 je jedn\u00edm z hlavn\u00edch v\u00fdzkumn\u00fdch n\u00e1stroj\u016f pro zkoum\u00e1n\u00ed t\u00e9to osy.<\/li>\n<\/ul>\n<p>T\u0159i dom\u00e9ny follistatinu (FSD1, FSD2, FSD3) ka\u017ed\u00e1 p\u0159isp\u00edvaj\u00ed k vazebn\u00e9mu profilu: FSD1 obsahuje hlavn\u00ed vazebnou plochu pro myostatin, FSD2 hlavn\u00ed vazebnou plochu pro aktivin a FSD3 p\u0159isp\u00edv\u00e1 jak k vazebn\u00e9 afinit\u011b, tak ke struktur\u00e1ln\u00ed stabilit\u011b. Heparin-vazebn\u00e1 N-termin\u00e1ln\u00ed dom\u00e9na odli\u0161uje splice varianty \u2014 FST-288 siln\u011b v\u00e1\u017ee heparan sulf\u00e1t a je p\u0159ev\u00e1\u017en\u011b ukotvena v membr\u00e1n\u011b, zat\u00edmco FST-344 (tato izoforma) cirkuluje voln\u011bji. Toto rozli\u0161en\u00ed je mechanisticky relevantn\u00ed ve v\u00fdzkumn\u00fdch modelech studuj\u00edc\u00edch syst\u00e9mov\u00e9 vs. lok\u00e1ln\u00ed \u00fa\u010dinky follistatinu.<\/p>\n<h2>Publikovan\u00e9 v\u00fdzkumn\u00e9 aplikace<\/h2>\n<p>Follistatin 344 se pou\u017e\u00edv\u00e1 v laboratorn\u00edm v\u00fdzkumu ke studiu:<\/p>\n<ul>\n<li><strong>V\u00fdzkum svalov\u00e9 hypertrofie a synt\u00e9zy protein\u016f<\/strong> \u2014 modely hypertrofie u my\u0161\u00ed a potkan\u016f v\u010detn\u011b studi\u00ed genov\u00e9 terapie AAV-follistatin (Kota et al., Sci Transl Med 2009); pr\u016f\u0159ezov\u00e1 plocha specifick\u00e1 pro typ vl\u00e1kna, hmotnost \u010derstv\u00e9ho svalu, generov\u00e1n\u00ed s\u00edly<\/li>\n<li><strong>Preklinick\u00e9 modely svalov\u00e9 dystrofie<\/strong> \u2014 model my\u0161i mdx pro Duchenneovu svalovou dystrofii; funk\u010dn\u00ed kapacita, regenerace vl\u00e1ken, ochrana sval\u016f nez\u00e1visl\u00e1 na dystrofinu<\/li>\n<li><strong>Sarkopenie a v\u011bkem podm\u00edn\u011bn\u00e1 ztr\u00e1ta svalov\u00e9 hmoty<\/strong> \u2014 fenotypy sval\u016f u st\u00e1rnouc\u00edch my\u0161\u00ed, anabolick\u00e1 rezistence, v\u00fdzkum zm\u011bn typu vl\u00e1ken<\/li>\n<li><strong>V\u00fdzkum kachexie u rakoviny<\/strong> \u2014 modely kachexie u my\u0161\u00ed s n\u00e1dory, zachov\u00e1n\u00ed t\u011blesn\u00e9ho slo\u017een\u00ed, pom\u011br svalov\u00e9 a tukov\u00e9 hmoty<\/li>\n<li><strong>V\u00fdzkum reproduk\u010dn\u00ed endokrinologie<\/strong> \u2014 suprese FSH, v\u00fdvoj ovari\u00e1ln\u00edch folikul\u016f, biologie granul\u00f3zn\u00edch bun\u011bk, v\u00fdzkum osy hypof\u00fdza-gon\u00e1dy<\/li>\n<li><strong>V\u00fdzkum aktivinov\u00e9 dr\u00e1hy<\/strong> \u2014 signalizace Smad2\/Smad3, EMT v modelech rakoviny, v\u00fdzkum fibr\u00f3zy, jatern\u00ed regenerace<\/li>\n<li><strong>V\u00fdzkum st\u00e1rnut\u00ed a osy GDF-11<\/strong> \u2014 fenotypy st\u00e1rnut\u00ed srdce a CNS, v\u00fdzkum souvisej\u00edc\u00ed s parabi\u00f3zou, rovnov\u00e1ha GDF-11\/myostatin se st\u00e1rnut\u00edm<\/li>\n<li><strong>Srovn\u00e1vac\u00ed v\u00fdzkum anabolick\u00fdch \u00fa\u010dink\u016f<\/strong> \u2014 p\u0159\u00edm\u00e9 srovn\u00e1n\u00ed s <a href=\"https:\/\/medsbase.com\/cs\/igf-1-lr3\/\">IGF-1 LR3<\/a> (paraleln\u00ed anabolick\u00e1 dr\u00e1ha prost\u0159ednictv\u00edm receptoru IGF-1) pro kombinovan\u00fd nebo srovn\u00e1vac\u00ed v\u00fdzkum hypertrofie.<\/li>\n<\/ul>\n<p>Pro \u0161ir\u0161\u00ed kontext, kam follistatin 344 zapad\u00e1 v r\u00e1mci v\u00fdzkumu anabolick\u00fdch a r\u016fstov\u00fdch os, viz <a href=\"https:\/\/medsbase.com\/cs\/igf-1-lr3\/\">IGF-1 LR3<\/a> jako kanonick\u00fd kompar\u00e1tor IGF osy, <a href=\"https:\/\/medsbase.com\/cs\/cjc-1295-with-dac\/\">CJC-1295 with DAC<\/a> pro v\u00fdzkum r\u016fstu prost\u0159ednictv\u00edm osy GHRH, a <a href=\"https:\/\/medsbase.com\/cs\/sermorelin\/\">Sermorelin<\/a> pro v\u00fdzkum krat\u0161\u00edho p\u016fsoben\u00ed GHRH. Prohl\u00e9dn\u011bte si cel\u00fd <a href=\"https:\/\/medsbase.com\/cs\/peptides\/\">katalog v\u00fdzkumn\u00fdch peptid\u016f<\/a> pro p\u0159\u00edbuzn\u00e9 slou\u010deniny.<\/p>\n<h2>Dostupn\u00e9 s\u00edly a koncentrace<\/h2>\n<p>MedsBase nab\u00edz\u00ed Follistatin 344 v lyofilizovan\u00fdch vialk\u00e1ch o obsahu 1 mg. Vialka je dostupn\u00e1 v balen\u00ed po 10 nebo 20 kusech s \u00fapln\u00fdmi pokyny k rekonstituci:<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">S\u00edla vialky<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Typick\u00fd v\u00fdzkumn\u00fd p\u0159\u00edpad u\u017eit\u00ed<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Velikosti balen\u00ed<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>1 mg<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Standardn\u00ed v\u00fdzkumn\u00e1 s\u00edla \u2013 v\u00fdzkum svalov\u00e9 hypertrofie a osy aktivin\/myostatin<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10 nebo 20 vialek<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Follistatin 344 je 37 kDa rekombinantn\u00ed glykoprotein dod\u00e1van\u00fd s \u010distotou \u226595 % HPLC. Form\u00e1t 1 mg vialky je standardn\u00ed v\u00fdzkumn\u00e1 s\u00edla pro in vivo a in vitro pr\u00e1ci \u2013 jedna vialka rekonstituovan\u00e1 s 1,0 mL bakteriostatick\u00e9 vody poskytuje pracovn\u00ed koncentraci 1 mg\/mL, kter\u00e1 posta\u010duje na mnoho t\u00fddn\u016f bun\u011b\u010dn\u00fdch kultur nebo n\u011bkolik injekc\u00ed v pokusech na hlodavc\u00edch.<\/p>\n<h2>Jak se srovn\u00e1v\u00e1 \u2013 Follistatin 344 vs IGF-1 LR3<\/h2>\n<p>Follistatin 344 a <a href=\"https:\/\/medsbase.com\/cs\/igf-1-lr3\/\">IGF-1 LR3<\/a> jsou dva nej\u010dast\u011bji citovan\u00e9 rekombinantn\u00ed anabolick\u00e9 proteiny v sou\u010dasn\u00e9m v\u00fdzkumu hypertrofie. P\u016fsob\u00ed na zcela odli\u0161n\u00fdch drah\u00e1ch \u2013 follistatin odstran\u011bn\u00edm brzdy myostatinu na r\u016fst sval\u016f, IGF-1 LR3 p\u0159\u00edmou stimulac\u00ed receptoru IGF-1 a n\u00e1slednou synt\u00e9zou protein\u016f p\u0159es Akt\/mTOR \u2013 co\u017e je \u010din\u00ed mechanisticky komplement\u00e1rn\u00edmi ve v\u00fdzkumn\u00fdch protokolech.<\/p>\n<table style=\"width: 100%; border-collapse: collapse; margin: 16px 0;\">\n<thead>\n<tr style=\"background: #2c7cb0; color: #fff;\">\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Krit\u00e9rium<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">Follistatin 344<\/th>\n<th style=\"padding: 10px; border: 1px solid #ddd; text-align: left;\">IGF-1 LR3<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>D\u00e9lka<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">344 aminokyselin (rekombinantn\u00ed glykoprotein)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">83 aminokyselin (modifikovan\u00fd IGF-1)<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Molekulov\u00e1 hmotnost<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~37 kDa<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">~9 kDa<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Prim\u00e1rn\u00ed mechanismus<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Sekvestrace myostatinu\/aktivinu<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Aktivace receptoru IGF-1 \u2192 Akt\/mTOR<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Zp\u016fsob \u00fa\u010dinku<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Disinhibice (odstran\u011bn\u00ed r\u016fstov\u00e9 brzdy)<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">P\u0159\u00edm\u00e1 anabolick\u00e1 stimulace<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Typick\u00e1 v\u00fdzkumn\u00e1 d\u00e1vka<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">10\u2013100 mcg, 1\u20133x t\u00fddn\u011b<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">20\u201360 mcg, denn\u011b<\/td>\n<\/tr>\n<tr style=\"background: #f9f9f9;\">\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Nejsiln\u011bj\u0161\u00ed v\u00fdzkumn\u00fd sign\u00e1l<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Modely hypertrofie cel\u00e9ho svalu a dystrofie<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">Lok\u00e1ln\u00ed hypertrofie a regenera\u010dn\u00ed anabolick\u00fd v\u00fdzkum<\/td>\n<\/tr>\n<tr>\n<td style=\"padding: 10px; border: 1px solid #ddd;\"><strong>Kombinov\u00e1n\u00ed<\/strong><\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u010casto pod\u00e1v\u00e1no spole\u010dn\u011b s IGF-1 LR3 ve v\u00fdzkumu hypertrofie<\/td>\n<td style=\"padding: 10px; border: 1px solid #ddd;\">\u010casto pod\u00e1v\u00e1no spole\u010dn\u011b s follistatinem 344<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Proto\u017ee tyto dva proteiny p\u016fsob\u00ed na z\u00e1sadn\u011b odli\u0161n\u00fdch anabolick\u00fdch os\u00e1ch \u2014 follistatin odstra\u0148uje brzdu myostatinu, zat\u00edmco IGF-1 LR3 p\u0159\u00edmo stimuluje synt\u00e9zu protein\u016f \u2014 kombinovan\u00e9 pod\u00e1v\u00e1n\u00ed se b\u011b\u017en\u011b pou\u017e\u00edv\u00e1 ve v\u00fdzkumn\u00fdch modelech zkoumaj\u00edc\u00edch maxim\u00e1ln\u00ed hypertrofickou odpov\u011b\u010f. Pro v\u00fdzkum zam\u011b\u0159en\u00fd konkr\u00e9tn\u011b na myostatinovou dr\u00e1hu je follistatin 344 kanonickou prvn\u00ed volbou; pro anabolick\u00fd v\u00fdzkum IGF\/Akt\/mTOR je IGF-1 LR3 kanonick\u00fdm v\u00fdzkumn\u00fdm n\u00e1strojem.<\/p>\n<h2>Skladov\u00e1n\u00ed a rekonstituce<\/h2>\n<p><strong>P\u0159ed rekonstituci:<\/strong> Skladujte lyofilizovan\u00e9 lahvi\u010dky v chladni\u010dce p\u0159i 2\u20138 \u00b0C v p\u016fvodn\u00edm obalu pro kr\u00e1tkodob\u00e9 pracovn\u00ed z\u00e1soby. Pro dlouhodob\u00e9 skladov\u00e1n\u00ed neotev\u0159en\u00fdch lahvi\u010dek zmrazte p\u0159i \u221220 \u00b0C. Lyofilizovan\u00fd follistatin 344 je stabiln\u00ed v chladni\u010dce a\u017e 12 m\u011bs\u00edc\u016f a p\u0159i \u221220 \u00b0C a\u017e 24 m\u011bs\u00edc\u016f \u2014 o n\u011bco krat\u0161\u00ed dobu ne\u017e mal\u00e9 syntetick\u00e9 peptidy, proto\u017ee v\u011bt\u0161\u00ed rekombinantn\u00ed glykoprotein je n\u00e1chyln\u011bj\u0161\u00ed k deamidaci a oxidaci v pr\u016fb\u011bhu \u010dasu. Vyvarujte se cykl\u016fm zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed lyofilizovan\u00e9ho pr\u00e1\u0161ku.<\/p>\n<p><strong>Postup rekonstituce:<\/strong> Aplikujte bakteriostatickou vodu po st\u011bn\u011b lahvi\u010dky s peptidem (ne p\u0159\u00edmo na lyofilizovan\u00fd kol\u00e1\u010d). Pro lahvi\u010dku 1\u00a0mg poskytne 1.0\u00a0mL bakteriostatick\u00e9 vody pracovn\u00ed koncentraci 1\u00a0mg\/mL. Jemn\u011b prom\u00edchejte krou\u017eiv\u00fdm pohybem \u2014 prove\u010fte <strong>ne<\/strong> Skladujte v chladni\u010dce p\u0159i 2\u20138 \u00b0C a pou\u017eijte do 30 dn\u016f pro optim\u00e1ln\u00ed stabilitu. Nefreeze rekonstituovan\u00fd roztok \u2014 rekombinantn\u00ed glykoproteiny jsou obzvl\u00e1\u0161t\u011b citliv\u00e9 na denaturaci p\u0159i zmrazov\u00e1n\u00ed a rozmrazov\u00e1n\u00ed, co\u017e vede k agregaci a ztr\u00e1t\u011b aktivity. Zlikvidujte jakoukoli lahvi\u010dku vykazuj\u00edc\u00ed z\u00e1kal, sra\u017eeninu nebo zm\u011bnu barvy.<\/p>\n<p><strong>Po rekonstituci:<\/strong> Nezmrazujte rekonstituovan\u00fd roztok \u2014 rekombinantn\u00ed glykoproteiny jsou obzvl\u00e1\u0161t\u011b citliv\u00e9 na denaturaci zmrazen\u00edm a rozmrazen\u00edm, kter\u00e1 zp\u016fsobuje agregaci a ztr\u00e1tu aktivity. Skladujte v chladni\u010dce p\u0159i teplot\u011b 2\u20138 \u00b0C a spot\u0159ebujte do 30 dn\u016f pro optim\u00e1ln\u00ed stabilitu. Zlikvidujte jakoukoli lahvi\u010dku vykazuj\u00edc\u00ed z\u00e1kal, sra\u017eeninu nebo zm\u011bnu barvy.<\/p>\n<h2 id=\"faqs\">\u010casto kladen\u00e9 dotazy<\/h2>\n<h3>K \u010demu se Follistatin 344 pou\u017e\u00edv\u00e1 ve v\u00fdzkumu?<\/h3>\n<p>Follistatin 344 se pou\u017e\u00edv\u00e1 v laboratorn\u00edm v\u00fdzkumu zkoumaj\u00edc\u00edm svalovou hypertrofii, preklinick\u00e9 modely svalov\u00e9 dystrofie, sarkopenii, n\u00e1dorovou kachexii, sign\u00e1ln\u00ed osu aktivin\/myostatin\/GDF-11, reproduk\u010dn\u00ed endokrinologii (suprese FSH, v\u00fdvoj ovari\u00e1ln\u00edch folikul\u016f) a fenotypy souvisej\u00edc\u00ed se st\u00e1rnut\u00edm. Je to kanonick\u00fd v\u00fdzkumn\u00fd n\u00e1stroj pro antagonizaci myostatinov\u00e9 dr\u00e1hy. Zde prod\u00e1van\u00fd follistatin 344 v\u00fdzkumn\u00e9 kvality je <strong>ne<\/strong> schv\u00e1len\u00fd FDA a je dod\u00e1v\u00e1n v\u00fdhradn\u011b pro laboratorn\u00ed v\u00fdzkumn\u00e9 \u00fa\u010dely.<\/p>\n<h3>Jak\u00fd je rozd\u00edl mezi Follistatin 344 a Follistatin 315?<\/h3>\n<p>FST-344 je genov\u00fd produkt, 344-aminokyselinov\u00e1 izoforma zahrnuj\u00edc\u00ed sign\u00e1ln\u00ed peptid; FST-315 je tent\u00fd\u017e protein po od\u0161t\u011bpen\u00ed sign\u00e1ln\u00edho peptidu b\u011bhem sekrece (FST-315 je tedy zral\u00e1 cirkuluj\u00edc\u00ed forma FST-344). Oba syst\u00e9my n\u00e1zvoslov\u00ed se v literatu\u0159e vyskytuj\u00ed a ozna\u010duj\u00ed tut\u00e9\u017e biologickou izoformu. Ob\u011b se podstatn\u011b li\u0161\u00ed od FST-288, co\u017e je krat\u0161\u00ed alternativn\u011b sest\u0159i\u017een\u00e1 izoforma se siln\u011bj\u0161\u00ed vazbou na heparansulf\u00e1t a p\u0159ev\u00e1\u017en\u011b membr\u00e1nov\u011b v\u00e1zanou lokalizac\u00ed.<\/p>\n<h3>Jak\u00fd je rozd\u00edl mezi Follistatinem 344 a IGF-1 LR3?<\/h3>\n<p>Oba jsou rekombinantn\u00ed anabolick\u00e9 proteiny pou\u017e\u00edvan\u00e9 ve v\u00fdzkumu svalov\u00e9 hypertrofie, ale zam\u011b\u0159uj\u00ed se na r\u016fzn\u00e9 dr\u00e1hy. Follistatin 344 je 344-aminokyselinov\u00fd glykoprotein, kter\u00fd v\u00e1\u017ee a sekvestruje myostatin a aktivin \u2014 funguje tak, \u017ee odstra\u0148uje endogenn\u00ed brzdu svalov\u00e9ho r\u016fstu. IGF-1 LR3 je 83-aminokyselinov\u00fd modifikovan\u00fd analog IGF-1, kter\u00fd p\u0159\u00edmo agonizuje receptor IGF-1 a aktivuje synt\u00e9zu protein\u016f Akt\/mTOR. Tyto dva jsou mechanismem komplement\u00e1rn\u00ed a ve v\u00fdzkumu se \u010dasto pod\u00e1vaj\u00ed spole\u010dn\u011b.<\/p>\n<h3>Jak\u00e1 je typick\u00e1 v\u00fdzkumn\u00e1 d\u00e1vka Follistatinu 344?<\/h3>\n<p>Publikovan\u00e9 preklinick\u00e9 protokoly obvykle pou\u017e\u00edvaj\u00ed 10\u2013100 mcg na aplikaci u hlodavc\u016f, pod\u00e1van\u00e9 1\u20133kr\u00e1t t\u00fddn\u011b po dobu 4\u201312 t\u00fddn\u016f. V\u00fdzkum genov\u00e9 terapie pomoc\u00ed AAV-follistatinu vytv\u00e1\u0159\u00ed tk\u00e1\u0148ov\u011b lokalizovan\u00e9 koncentrace, kter\u00e9 je obt\u00ed\u017en\u00e9 p\u0159\u00edmo porovnat se syst\u00e9mov\u00fdm pod\u00e1v\u00e1n\u00edm proteinu. 1 mg lahvi\u010dka rekonstituovan\u00e1 s 1,0 mL bakteriostatick\u00e9 vody poskytne koncentraci 1 mg\/mL \u2014 0,01 mL odpov\u00edd\u00e1 10 mcg, 0,1 mL odpov\u00edd\u00e1 100 mcg.<\/p>\n<h3>Je Follistatin 344 schv\u00e1len FDA?<\/h3>\n<p>Ne. Follistatin 344 nen\u00ed schv\u00e1len FDA, EMA, MHRA ani \u017e\u00e1dn\u00fdm jin\u00fdm v\u00fdznamn\u00fdm regul\u00e1torem pro terapeutick\u00e9 pou\u017eit\u00ed u lid\u00ed. Genov\u00e1 terapie AAV-follistatinem byla zkoum\u00e1na v klinick\u00fdch studi\u00edch u svalov\u00fdch dystrofi\u00ed (nap\u0159. Beckerova svalov\u00e1 dystrofie, myositida s inkluzn\u00edmi t\u011bl\u00edsky), ale nen\u00ed schv\u00e1lena FDA. Ve\u0161ker\u00fd follistatin 344 prod\u00e1van\u00fd dodavateli pouze pro v\u00fdzkumn\u00e9 \u00fa\u010dely je ur\u010den pro laboratorn\u00ed v\u00fdzkum a nem\u011bl by b\u00fdt pod\u00e1v\u00e1n lidem.<\/p>\n<h3>Jak by m\u011bl b\u00fdt Follistatin 344 skladov\u00e1n?<\/h3>\n<p>Lyofilizovan\u00e9 lahvi\u010dky: kr\u00e1tkodob\u011b p\u0159i 2\u20138 \u00b0C, dlouhodob\u011b p\u0159i \u221220 \u00b0C pro neotev\u0159en\u00e9 lahvi\u010dky. Rekonstituovan\u00fd roztok: skladujte p\u0159i 2\u20138 \u00b0C, pou\u017eijte do 30 dn\u016f. Nefreezujte rekonstituovan\u00fd roztok \u2014 rekombinantn\u00ed glykoproteiny jsou obzvl\u00e1\u0161t\u011b citliv\u00e9 na denaturaci p\u0159i zmrazen\u00ed. Chra\u0148te p\u0159ed p\u0159\u00edm\u00fdm sv\u011btlem. Pro \u0159ed\u011bn\u00ed pod 100 mcg\/mL se doporu\u010duje nosn\u00fd protein (BSA 0,1%).<\/p>\n<h3>Jak rekonstituovat Follistatin 344?<\/h3>\n<p>Postupujte podle v\u00fd\u0161e uveden\u00e9ho rekonstitu\u010dn\u00edho postupu. P\u0159idejte bakteriostatickou vodu po st\u011bn\u011b lahvi\u010dky (ne p\u0159\u00edmo na lyofilizovan\u00fd pr\u00e1\u0161ek), jemn\u011b prom\u00edchejte a nechte 5\u201310 minut pro \u00fapln\u00e9 rozpu\u0161t\u011bn\u00ed. Ne <strong>ne<\/strong> prot\u0159ep\u00e1vejte lahvi\u010dku \u2014 intenzivn\u00ed m\u00edch\u00e1n\u00ed m\u016f\u017ee denaturovat rekombinantn\u00ed proteiny a zp\u016fsobit agregaci. Spr\u00e1vn\u011b rekonstituovan\u00fd roztok je \u010dir\u00fd a bezbarv\u00fd. Pro 1 mg lahvi\u010dku + 1,0 mL rozpou\u0161t\u011bdla je pracovn\u00ed koncentrace 1 mg\/mL.<\/p>\n<h3>Pro\u010d je specifikace \u010distoty 95% nam\u00edsto 99%?<\/h3>\n<p>Rekombinantn\u00ed glykoproteiny jako follistatin 344 nemohou dos\u00e1hnout standardu HPLC \u010distoty \u226599% typick\u00e9ho pro mal\u00e9 syntetick\u00e9 peptidy kv\u016fli inherentn\u00ed heterogenit\u011b glykosylace v jak\u00e9mkoli rekombinantn\u00edm expresn\u00edm syst\u00e9mu \u2014 r\u016fzn\u00e9 glykoformy se na HPLC jev\u00ed jako souvisej\u00edc\u00ed p\u00edky, kter\u00e9 nejsou ne\u010distoty, ale izoformy c\u00edlov\u00e9ho proteinu. \u226595% HPLC \u010distota je standardn\u00ed v\u00fdzkumn\u00e1 specifikace pro follistatin 344 a podobn\u00e9 rekombinantn\u00ed glykoproteiny. SDS-PAGE typicky ukazuje jednu linii v o\u010dek\u00e1van\u00e9m rozsahu 38\u201342 kDa.<\/p>\n<h3>Jak\u00e9 s\u00edly nab\u00edz\u00ed MedsBase?<\/h3>\n<p>MedsBase nab\u00edz\u00ed Follistatin 344 v 1 mg lyofilizovan\u00fdch lahvi\u010dk\u00e1ch. Lahvi\u010dky jsou dostupn\u00e9 v balen\u00ed po 10 nebo 20 kusech. V\u0161echny lahvi\u010dky jsou dod\u00e1v\u00e1ny s HPLC \u010distotou \u226595% a certifik\u00e1tem anal\u00fdzy na vy\u017e\u00e1d\u00e1n\u00ed.<\/p>\n<h3>Lze Follistatin 344 a IGF-1 LR3 kombinovat ve v\u00fdzkumu?<\/h3>\n<p>Ano. Follistatin 344 a IGF-1 LR3 p\u016fsob\u00ed na z\u00e1sadn\u011b odli\u0161n\u00e9 anabolick\u00e9 osy (antagonismus myostatinu vs. agonismus IGF-1 receptoru) a jsou \u010dasto spole\u010dn\u011b pod\u00e1v\u00e1ny ve v\u00fdzkumn\u00fdch modelech zkoumaj\u00edc\u00edch maxim\u00e1ln\u00ed hypertrofickou odpov\u011b\u010f. Mechanicky se dopl\u0148uj\u00ed sp\u00ed\u0161e ne\u017e p\u0159ekr\u00fdvaj\u00ed a literatura popisuje aditivn\u00ed nebo synergick\u00e9 \u00fa\u010dinky na pr\u016f\u0159ezovou plochu svalov\u00fdch vl\u00e1ken.<\/p>\n<h3>Zp\u016fsobuje Follistatin 344 ve v\u00fdzkumu vedlej\u0161\u00ed \u00fa\u010dinky?<\/h3>\n<p>Publikovan\u00e9 preklinick\u00e9 v\u00fdzkumy dokumentuj\u00ed dobrou sn\u00e1\u0161enlivost p\u0159i typick\u00fdch v\u00fdzkumn\u00fdch d\u00e1vk\u00e1ch, p\u0159i\u010dem\u017e hlavn\u00edm c\u00edlov\u00fdm \u00fa\u010dinkem je svalov\u00e1 hypertrofie. Vedlej\u0161\u00ed n\u00e1lezy zahrnuj\u00ed modulaci FSH a ovari\u00e1ln\u00ed funkce (v d\u016fsledku potla\u010den\u00ed signalizace aktivinu) a potenci\u00e1ln\u00ed \u00fa\u010dinky na jatern\u00ed regeneraci a hypofyz\u00e1rn\u00ed regulaci, co\u017e souvis\u00ed s rol\u00ed folistatinu v \u0161ir\u0161\u00ed signalizaci TGF-\u03b2 superrodiny. Syst\u00e9mov\u00e9 pod\u00e1v\u00e1n\u00ed folistatinu jako proteinu m\u00e1 odli\u0161n\u00e9 farmakokinetick\u00e9 charakteristiky ne\u017e tk\u00e1\u0148ov\u011b lokalizovan\u00e9 p\u0159\u00edstupy pomoc\u00ed AAV genov\u00e9 terapie.<\/p>\n<h3>Jak\u00fd je polo\u010das rozpadu folistatinu 344?<\/h3>\n<p>V preklinick\u00e9m v\u00fdzkumu m\u00e1 rekombinantn\u00ed folistatin 344 po intraven\u00f3zn\u00edm pod\u00e1n\u00ed plazmatick\u00fd polo\u010das p\u0159ibli\u017en\u011b 1\u20133 hodiny, co\u017e odpov\u00edd\u00e1 jeho velikosti (37 kDa, nad prahem ren\u00e1ln\u00ed filtrace) a vazb\u011b na cirkuluj\u00edc\u00ed ligandy. Tk\u00e1\u0148ov\u00fd polo\u010das je v\u00fdrazn\u011b del\u0161\u00ed, proto\u017ee folistatin z\u016fst\u00e1v\u00e1 v\u00e1z\u00e1n na sv\u00e9 c\u00edlov\u00e9 molekuly myostatin a aktivin, \u010d\u00edm\u017e je sekvestruje mimo receptory. Genov\u00e9 terapeutick\u00e9 p\u0159\u00edstupy poskytuj\u00ed mnohem del\u0161\u00ed \u00fa\u010dinek d\u00edky kontinu\u00e1ln\u00ed tk\u00e1\u0148ov\u00e9 expresi po t\u00fddny a\u017e m\u011bs\u00edce.<\/p>\n<h3>Za jak dlouho se projev\u00ed \u00fa\u010dinky folistatinu 344 v preklinick\u00e9m v\u00fdzkumu?<\/h3>\n<p>\u00da\u010dinky na svalovou hypertrofii u my\u0161\u00ed a potkan\u016f p\u0159i t\u00fddenn\u00edm pod\u00e1v\u00e1n\u00ed proteinu se obvykle st\u00e1vaj\u00ed statisticky v\u00fdznamn\u00fdmi po 2\u20134 t\u00fddnech a d\u00e1le se zvy\u0161uj\u00ed po dobu 8\u201312 t\u00fddn\u016f. \u00da\u010dinky na reproduk\u010dn\u00ed parametry prost\u0159ednictv\u00edm osy aktivin\/FSH lze detekovat ji\u017e b\u011bhem n\u011bkolika dn\u00ed po pod\u00e1n\u00ed. P\u0159i genov\u00e9 terapii (AAV-folistatin) je m\u011b\u0159iteln\u00e1 svalov\u00e1 hypertrofie patrn\u00e1 za 4\u20136 t\u00fddn\u016f po injekci a d\u00e1le se rozv\u00edj\u00ed v pr\u016fb\u011bhu m\u011bs\u00edc\u016f.<\/p>\n<h3>Mohu si objednat folistatin 344 pro mezin\u00e1rodn\u00ed p\u0159epravu?<\/h3>\n<p>Ano. MedsBase expeduje folistatin 344 do cel\u00e9ho sv\u011bta prost\u0159ednictv\u00edm na\u0161\u00ed specializovan\u00e9 s\u00edt\u011b pro p\u0159epravu peptid\u016f. Samostatn\u00e9 objedn\u00e1vky peptid\u016f jsou zp\u016fsobil\u00e9 pro na\u0161i samostatnou p\u0159epravn\u00ed slu\u017ebu. V\u0161echny z\u00e1silky jsou expedov\u00e1ny v termoregulovan\u00e9m obalu s kompletn\u00edm sledov\u00e1n\u00edm a jsou kryty na\u0161\u00ed <a href=\"https:\/\/medsbase.com\/cs\/medsbase-re-shipment-assurance-policy\/\">Z\u00e1rukou op\u011btovn\u00e9ho odesl\u00e1n\u00ed<\/a>.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h2>Dal\u0161\u00ed peptidy pro anabolick\u00fd v\u00fdzkum, v\u00fdzkum r\u016fstov\u00e9 osy a sval\u016f<\/h2>\n<ul>\n<li><a href=\"\/cs\/igf-1-lr3\/\"><strong>IGF-1 LR3<\/strong><\/a> \u2014 Dlouho-argininov\u00fd rekombinantn\u00ed analog IGF-1 \u2013 p\u0159\u00edm\u00fd agonista IGF-1R pro v\u00fdzkum Akt\/mTOR dr\u00e1hy<\/li>\n<li><a href=\"\/cs\/cjc-1295-with-dac\/\"><strong>CJC-1295 with DAC<\/strong><\/a> \u2014 Dlouhodob\u011b p\u016fsob\u00edc\u00ed analog GHRH \u2013 v\u00fdzkum r\u016fstov\u00e9 osy<\/li>\n<li><a href=\"\/cs\/sermorelin\/\"><strong>Sermorelin<\/strong><\/a> \u2014 Krat\u0161\u00ed p\u016fsob\u00edc\u00ed analog GHRH(1-29) \u2014 v\u00fdzkum p\u0159irozen\u00fdch pulz\u016f r\u016fstov\u00e9ho hormonu<\/li>\n<li><a href=\"\/cs\/ipamorelin\/\"><strong>Ipamorelin<\/strong><\/a> \u2014 Selektivn\u00ed agonista ghrelinu \u2014 \u010dist\u00fd pulz r\u016fstov\u00e9ho hormonu bez kortizolu\/prolaktinu<\/li>\n<li><a href=\"\/cs\/tb-500\/\"><strong>TB-500 (Thymosin Beta-4)<\/strong><\/a> \u2014 Syst\u00e9mov\u00fd hojiv\u00fd fragment \u2014 v\u00fdzkum obnovy sval\u016f a srde\u010dn\u00ed tk\u00e1n\u011b<\/li>\n<\/ul>\n<p><!-- medsbase-peptide-guide-cta --><\/p>\n<h2>Dal\u0161\u00ed \u010dten\u00ed<\/h2>\n<div style=\"background: #f4f8fb; border-left: 4px solid #2c7cb0; padding: 18px 22px; margin: 18px 0; border-radius: 4px;\">\n<p style=\"margin: 0 0 8px 0;\"><strong>\ud83d\udcd6 Prozkoumejte anabolick\u00e9 peptidy a peptidy r\u016fstov\u00e9 osy pro v\u00fdzkum<\/strong><\/p>\n<p style=\"margin: 0;\">Prohl\u00e9dn\u011bte si celou <a href=\"https:\/\/medsbase.com\/cs\/peptides\/\"><strong>katalog v\u00fdzkumn\u00fdch peptid\u016f<\/strong><\/a>, v\u010detn\u011b p\u0159\u00edbuzn\u00fdch slou\u010denin jako <a href=\"https:\/\/medsbase.com\/cs\/igf-1-lr3\/\">IGF-1 LR3<\/a> pro p\u0159\u00edm\u00fd v\u00fdzkum anabolick\u00fdch \u00fa\u010dink\u016f na IGF-receptory, <a href=\"https:\/\/medsbase.com\/cs\/cjc-1295-with-dac\/\">CJC-1295 with DAC<\/a> pro v\u00fdzkum dlouhodob\u011b p\u016fsob\u00edc\u00edho GHRH a <a href=\"https:\/\/medsbase.com\/cs\/tb-500\/\">TB-500<\/a> pro v\u00fdzkum syst\u00e9mov\u00e9 obnovy sval\u016f a tk\u00e1n\u00ed.<\/p>\n<\/div>\n<p><!-- pep-seo-v1 --><\/p>","protected":false},"excerpt":{"rendered":"<p>\u2705 344-aa rekombinantn\u00ed glykoprotein<br \/>\n\u2705 Antagonista myostatinov\u00e9 a aktivinov\u00e9 dr\u00e1hy<br \/>\n\u2705 V\u00fdzkumn\u00e1 slou\u010denina pro svalovou hypertrofii<br \/>\n\u2705 Preklinick\u00e9 modely svalov\u00e9 dystrofie<br \/>\n\u2705 \u226595% HPLC \u010distota, COA na vy\u017e\u00e1d\u00e1n\u00ed<\/p>\n<p><strong>Follistatin 344<\/strong> je rekombinantn\u00ed protein.<\/p>","protected":false},"featured_media":70949,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[5426],"product_tag":[6276,5441],"class_list":{"0":"post-70719","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-peptides","7":"product_tag-follistatin","8":"product_tag-peptide","10":"first","11":"instock","12":"shipping-taxable","13":"purchasable","14":"product-type-variable","15":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product\/70719","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/comments?post=70719"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media\/70949"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/media?parent=70719"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_brand?post=70719"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_cat?post=70719"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/cs\/wp-json\/wp\/v2\/product_tag?post=70719"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}